The global molecular cytogenetics market is projected to grow at a compound annual growth rate (CAGR) of 9.9% from 2023 to 2028, reaching $4.9 billion by 2028, according to a new report by MarketsandMarkets. The market was valued at $3.1 billion in 2023. Key growth drivers include the increasing incidence of cancer and genetic disorders globally, untapped emerging markets, and technological advancements in molecular cytogenetics techniques.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224
Molecular cytogenetics involves studying chromosomal abnormalities at the molecular level to understand genetic mutations associated with diseases like cancer and genetic disorders. The incorporation of molecular biology techniques like polymerase chain reaction and fluorescence in situ hybridization in cytogenetics has enhanced the scope and sensitivity of this field.
The rising prevalence of chronic diseases with a genetic basis is spurring demand for molecular cytogenetics products including kits, reagents, instruments, consumables and software services. The kits and reagents segment held the largest share of the molecular cytogenetics market in 2022. New product launches and an expanding application scope across clinical pathology and cancer research are key factors attributed to the dominant position of this segment.
Comparative genomic hybridization (CGH) represented the leading technique in 2022, offering significant advantages over traditional cytogenetic analysis platforms. The transition from fluorescence in situ hybridization (FISH) to array-based CGH techniques is expected to open up substantial opportunities, enabled by faster hybridization and detection of small genetic aberrations.
Among key end-use segments, clinical and research laboratories accounted for the largest share in 2022. The high use of molecular cytogenetics techniques for cancer and genetic disease diagnosis coupled with a rise in the number of specialty labs and testing volumes is driving the demand from clinical laboratories. Research laboratories are also extensively using these platforms for developing personalized therapeutics, predicting patient outcomes and stratification of affected populations.
Geographically, North America had the highest revenue share in 2022, enabled by supportive research infrastructure, presence of market leaders and high disease burden. Asia Pacific is slated to witness the fastest growth over the coming years on account of improving healthcare expenditure, demand for advanced genomic testing and strategic developments by leading global players in the region.
The molecular cytogenetics space is marked by high barriers to entry including substantial R&D investments, rigorous quality compliance requirements and intense competition. Key players operating in this market include Roche, Danaher Corporation, Agilent Technologies, Abbott Laboratories and Thermo Fisher Scientific. These companies are focused on new product development, mergers and acquisitions along with global expansion to consolidate their market positions.
The growing need for early and accurate diagnosis, shift towards personalized medicine and emergence of biotech hubs in developing markets is expected to present significant opportunities for growth of the global molecular cytogenetics industry over the coming decade. Companies that leverage technology to offer high-value products while ensuring quality, safety and cost-effectiveness will be well-placed to capitalize on this trend.
